



PRESS RELEASE, JULY 31, 2013

Change of number of shares and votes in Moberg Pharma

The number of shares and votes in Moberg Pharma AB (publ) has increased by 1,081,000 to 11,893,572 during July 2013. Therefore, there are in total 11,893,572 shares and votes in the company as of July 31st, 2013.

The increase is a result of a directed share issue of 1,081,000 shares to Bure Equity AB resolved by the board under an authorization from the annual general meeting 2013. The share issue was completed in order for Moberg Pharma to increase its financial flexibility relating to potential acquisition opportunities.

For additional information contact:

Peter Wolpert, CEO

Telephone: +46 (0)70 - 735 71 35

E-mail: peter.wolpert@mobergpharma.se

Magnus Persson, IR

Telephone: +46 (0)73 – 355 26 01

E-mail: magnus.persson@mobergpharma.se

About this information

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08.30 am (CET) on July 31st, 2013.

About Moberg Pharma

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 40 countries. The company's product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal[®], Jointflex[®], Kerasal Nail[®] and Kaprolac[®]. Kerasal Nail[®] (Nalox[™] in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company's share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.